Endotheliurq-dependent relaxation is mediated by the release from vascular endothelium of an endothelium-drived relaxing factor (EDRF). It is qot clear what role arachidonic acid has in this process. Inhibition of phospholipase A2, and diacylglycerol lipase in cultured bovine aortic'endothelial cells caused a marked reduction in agonist-induced arachidonic acid release from membrane phospholipid pools, and complete inhibition of prostacyclin production. EDRF release, assayed by measuring endothelium-dependent cGMP changes in mixed endothelialsmooth muscle cell cultures, was not inhibited under these conditions. In fact, EDRF release in response to two agonists, melittin and ATP, was actually increased in cells treated with phospholipase A2 inhibitors. In addition, pretreatment of rats with high-dose dexamethasone, an inhibitor of PLA2, did not attenuate endothelium-dependent relaxation in intact aortic rings rimoved from the animals, or depressor responses in anesthetized animals induced by endothelium-dependent vasodilators. In summary, inhibition of arachidonic acid release from membrane phospholipid pools does not attenuate endothelium-dependent relaxation in rats, or the release and/or response to EDRF in cultured cells.
phospholipases and, arachidonic acid (AA) release from membrane phospholipid pools (5) (6) (7) (8) (9) . It is not known if AA is a precursor of EDRF or, alternatively, a signal for factor production and/or release. A cytochrome P-450-dependent monooxygenase has been identified in endothelium (10) that can oxidize AA to its monohydroxy metabolites and, to a series of epoxides and their corresponding diols (1 1-13) . Some of these novel products are arterial vasodilators. Thus, by definition they are endothelium-derived relaxing factors. There is, however, recent evidence to suggest that EDRF may be endogenous, biologically produced nitric oxide (14) .
AA released from endothelial cell phospholipids is metabolized by cycloxygenase to prostacyclin (PGI2), and lesser amounts of prostaglandin F2a and thromboxane A2 (15, 16) . According to the evidence cited above (10) (11) (12) (13) , an undetermined amount of AA also may be metabolized by a cytochrome P-450-dependent monooxygenase to a vasodilator. In endothelial cells, the major sources of AA are hydrolysis of phosphatidylinositol (PI) by activated phospholipase A2 (PLA2) and phospholipase C (PLC), and hydrolysis of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) by PLA2 (17) . PLC hydrolysis ofPI releases diacylglycerol (DAG), which requires cleavage by DAG lipase to yield free AA. In the endothelium as well as other tissues, calcium may play a major role in the activation of PLA2.
Glucocorticoids inhibit inflammation by inducing the production of a family of soluble exportable proteins called lipocortins that inhibit PLA2 (18) (19) (20) (21) . This inhibition of PLA2 reduces prostaglandin and leukotriene production. Although lipocortin has not yet been purified from endothelium, the capacity of endothelial cells to respond to glucocorticoid treatment has been demonstrated (22) . Crutchley and colleagues observed a maximal 65% inhibition of bradykinin-induced PGI2 release from bovine pulmonary artery endothelial cells following 24-h incubation with dexamethasone (105-1-09 M) (22) . The corresponding maximal inhibition of PGI2 release induced by the calcium ionophore A23 187, was 35%.
Thus if EDRF production is dependent on AA release, and if AA release is inhibited by steroids, then EDRF release also should be steroid sensitive. To test this hypothesis we first confirmed that cultured bovine aortic endothelial cells (BAECs) produce a PLA2 inhibitor capable of inhibiting AA release and PGI2 formation in response to steroids. Although cultured BAECs release EDRF (23) (24) (25) (26) (27) , its production cannot be measured directly. To assay EDRF release by cultured BAECs, we measured cGMP changes in mixed BAEC-smooth muscle cell (SMC) cultures in response to endothelium-de-removed form rats after 48 h of treatment with steroids. The relaxations induced by endothelium-dependent vasodilators in these rings were compared to similarly induced relaxations in rings from untreated control rats. Finally, we measured the cardiovascular responses of steroid treated and control rats to intravenous injections of the endothelium-dependent vasodilator methacholine.
Methods BAEC monolayer cultures. Bovine thoracic aortae were obtained from a local slaughterhouse and endothelial cells were isolated for culture as previously described (23, 24) . BAECs were plated at a density of 2 X 104 cells/cm2 in Waymouth's media (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT) plus penicillin (100 U/ml) and streptomycin (100 g/ml). Cells were incubated at 37"C under an atmosphere of 95% air, 5% CO2, and the media changed every other day until the cells became confluent on or about day 12. Confluent cultures were passaged using trypsin (0.01% VMF trypsin; Worthington Biochemicals, Freehold, NJ) and 0.02% ethylenediamine tetraacetic acid to disperse the cells. Only cells obtained from the second to the twelfth passage were used for either monolayer or mixed culture experiments.
To prepare BAECs for monolayer experiments, cells were plated into 4 cm2 wells on 12 well tissue culture plates (Costar, Cambridge, MA) at a cell density of 2 X 104/cm2 in 2 ml/well of media. Between days 12 and 16 the medium was changed for I ml/well of a serum-free medium (SFM) consisting of equal pats of Nutrient Mixture F12 and Dulbecco's modified Eagle medium (Gibco) supplemented with insulin (5 mg/liter) and transferrin (35 mWliter) plus penicillin (100 U/ml) and streptomycin (100 Ag/ml) (29 (24, 28) . However, when the two cell types are mixed, EDRF released by the endothelium elevates cGMP levels in the SMCs (24, 28) . Rat thoracic aortic SMCs were isolated and cultured according to a previously described method (32) . The SMCs were cultured for 10 d in 12 well plates (4 cm2 wells) in 2 ml of medium-l 99 (Gibco) supplemented with 10% FCS, penicillin (100 U/ml) and streptomycin (100 gg/ml). On the tenth day only 1 ml of media was placed in each well. Flasks (25 To ensure that the observed cGMP changes following melittin and ATP exposure were indeed endothelium dependent, control 10-d-old cultures of rat SMCs alone were treated in exactly the same fashion as the mixed cultures.
Preparation of rat aortic rings: Adult Sprague-Dawley rats (250-500 g) of either sex were injected subcutaneously with 0.4 mg/kg of dexamethasone in 0.1 ml sterile water. This dose corresponded to a final dexamethasone concentration in the animal of 10-6 M. Control rats were injected with 0.1 ml of sterile water. 48 h after injection the rats were killed by decapitation and the aortae removed by careful dissection and placed in Krebs-Ringer-bicarbonate buffer (pH 7.4). The composition of the buffer was (millimolar); NaCl, 11 1; KCI, 5; NaH2PO4, 1; MgCl2, 0.5; NaHCO3, 25; CaC12, 2.5; and dextrose, 1 1.1. Aortae removed from steroid-treated animals were kept at all times, in buffer containing 164 MM dexamethasone. Periaortic fat was removed and care was taken during dissection to ensure the integrity of the vascular endothelium by avoiding unnecessary stretching or contact of the instruments with the luminal surfaces of the aortae. The aortae were cut into rings (2-3 mm) and suspended under 2 g tension in 10 ml water-jacketed isolated organ baths maintained at 370C. The rings were equilibrated for 2 h in a solution of Krebs-Ringer-bicarbonate which was gassed continuously with 95% 02-5% CO2. The buffer was changed at 30-min intervals during equilibration and the rings stretched to give a final resting tension of 2 g. Isometric force was measured with Grass model FT 03C force transducers (Grass Instruments, Quincy, MA) coupled via a transducer amplifier (model 13-4615-50: Gould Instruments, Cleveland, OH) to Gould 8 channel thermal writing recorder series 8000S.
Relaxation responses were determined in control and experimental rings contracted to a stable plateau tension with 10-' M of the alpha adrenergic agonist phenylephrine (Sigma). This concentration ofphenylephrine elicits -40% of the maximum force attainable with this agonist. In all rings the integrity of the endothelium was assessed by observing methacholine (Sigma; 10-6 M) induced endothelium-dependent relaxations. Only rings with intact endothelium were used in this study. Rings were then washed three times over 30 min and tension returned to baseline (2 g). Rings were contracted with l-7 M phenylephrine and relaxations recorded in response to 2 ,ug/ml melittin and, a range ofconcentrations of methacholine (10-8-3 X 10-6 M), and A23187 (l0-8-l0-6 M; Sigma). For melittin, the latency, the rate and, the extent of each relaxation was calculated by measuring; the time to onset of contraction, t/2 ofrelaxation and, the maximum relaxation induced. Maximal relaxations were expressed as a percentage of the developed tension. Only maximal relaxations were recorded for the dose-response curves. Cardiovascular response to methacholine. Adult male Wistar rats (300 g) were injected with either dexamethasone or sterile water as described above. 72 h after injection, control and experimental rats were anesthetized with 50-60 mg/kg intraperitoneal sodium pentobarbital (Elkins-Sinn, Cherry Hill, NJ). The femoral artery and vein were canulated and the artery connected to a pressure transducer (P23DB; Statham, Oxnard, CA) hooked to a recorder (Brush 220; Gould, Cleveland, OH) for direct arterial pressure recording. Pulse rate was read from a high'speed recording. The vein was used for intravenous administration and flushed with 100 ul normal saline (3 vol of cannula dead space) following injection of 100 Ml bolus of an aqueous solution of methacholine (10-710-M induced endothelium-dependent relaxation seen in intact rings of rat aorta (35, 36) . Basal cGMP in control SMC monolayer cultures, 1.9±0.2 pmol/mg protein, was almost 10-fold less than the levels in the mixed BAEC-SMC cultures. The melittin-induced cGMP elevations seen in the mixed cultures were clearly endothelium dependent, since such changes were not seen in SMC monolayer cultures (not shown).
To determine whether this failure ofhigh-dose dexamethasone to alter melittin-induded EDRF release was a general property of PLA2 inhibitors, we investigated the effect of quinacrine in this system. Fig. 4 A compares the effects of dexamethasone, quinacrine, and a combination of the two on PGI2 release from BAEC-SMC mixed cultures 90 s after administration of 2 gg/ml melittin. Quinacrine, l0-, M, produced slightly more inhibition of PLA2 than did 10-6 M dexamethasone. While the effect of the combination of the two inhibitors was not additive, it produced a maximum 62% (P <0.01) inhibition of PGI2 release (Fig. 4) figure. 2 h before exposure to melittin, 10--M quinacrine (QUIN) was added to selected wells. 90 s after adding 2 gg/ml melittin (MEL), cells and media were separated and the proteins, cGMP, and 6-keto-PGF15 determined. Shown in A are the amounts of PGI2 released by PBS alone (CONT), melittin, and by melittin in the presence of dexamethasone, quinacrine, or a combination of the two. All treatments caused a significant reduction in melittin-induced PGI2 release, UP < 0.01 (n = 6). B shows the corresponding cGMP levels in the cells. Combined dexamethasone and quinacrine treatment significantly enhanced cGMP changes, tP < 0.01 (n = 6) compared to melittin alone, or melittin and individual inhibitors. inhibition ofPGI2 release. Inhibition of DAG lipase with RHC 80267 produced 50% (P < 0.01) inhibition of PG12 release from the mixed cultures. A combination of the two inhibitors produced -90% inhibition (P < 0.01) of melittin-induced PG12 release. This was effectively complete inhibition, because the amount of PGI2 released at 90 s by 2 /g/ml melittin in the presence of a combination of RHC 80267 and dexamethasone was not significantly different from the unstimulated control (PBS alone). The inhibitors had an additive effect, since the amount of PG12 released from the mixed cultures after combined treatment, was significantly less than the amount released in the presence ofeach inhibitor alone (P < 0.01). From Fig. 5 Fig. 6, A and B show the effect of increasing doses of dexamethasone and hydrocortisone, respectively, on ATP-stimulated PGO2 production and cGMP accumulation in mixed cultures. This dose of ATP, l0-4 M, was equipotent with 2 ug/ml melittin in terms of EDRF release (54±5 vs. 51±5 pmol cGMP/mg protein), but induced -50% less PGI2 release (P < 0.01; see Fig. 4 for comparison). Dexamethasone and hydrocortisone both caused complete inhibition of PGO2 production while potentiating EDRF release by as much as 75%. Potentiation of cGMP elevations were not seen with high doses of hydrocortisone (10-5 and 10-4 M).
Quinacrine (10-5 M) and a combination ofquinacrine with dexamethasone (10-M), both agents inhibit PLA2 but not PLC activity, completely inhibited ATP-induced PGI2 release from the mixed cultures (not shown). Once again, ATP-induced endothelium-dependent cGMP accumulation was significantly enhanced (P < 0.01) by PLA2 inhibitors (quinacrine alone 80±7, and the combination of quinacrine and dexamethasone 79±6 pmol cGMP/mg protein). SNP-induced cGMP changes were not affected by dexamethasone, hydrocortisone, or quinacrine (not shown).
cAMP changes in mixed BAEC-SMC cultures. The basal cAMP level in mixed cultures (12±4 pmol/mg protein) was not altered by SNP or dexamethasone treatment. Stimulation of the mixed cultures with either ATP or melittin, however, caused minor but significant (P < 0.05) increases in cAMP levels to 22±3, and 21±4 pmol/mg protein, respectively. PLA2 inhibitors have no effect on this response (not shown).
Relaxations in intact rings ofrat aorta. The profile of melittin-induced relaxation in rings of endothelium-intact rat aorta is shown in Table I the rate, or the extent of the relaxations induced by melittin.
The maximum relaxations induced by 2 Aeg/ml melittin were 43±11% and 47±12% for steroid treated and control animals, respectively. Dose-response curves for methacholine (10-8 to 3 X 10-6 M) induced endothelium-dependent relaxations were constructed for aortic rings removed from dexamethasone treated and control rats. These curves are shown in Fig. 7 . Methacholine-induced relaxation of intact rings of rat aorta were not significantly altered by prior treatment of the animals with dexamethasone. The dose response curve (10-8 to 10-6 M) for A23187, another endothelium-dependent vasodilator, was also not altered by steroid treatment (not shown).
Cardiovascular response to methacholine. The cardiovascular response of steroid treated and control rats to intravenous injections of increasing doses of methacholine is shown in Fig. 8 . No appreciable change in heart rate occurred until 100 Ml of 10-4 M methacholine (final dose 6.5 Mg/kg) was injected (top panel). The corresponding blood pressure responses are shown in the bottom panel of Fig. 8 . Starting at the lowest dose (10-7 M) , there was a progressive dose-dependent fall in blood pressure. Steroid treated and control animals displayed the same blood pressure response at all doses of methacholine. Discussion This study demonstrates that endothelial cells respond to corticosteroids by producing a PLA2 inhibitor, presumably lipocortin, which is responsible for a reduction of 45% in the amount of AA released from phospholipid pools following exposure to melittin. This inhibition is accompanied by a corresponding fall in the release of a known AA product, PG12.
Reduced endothelial cell PGI2 formation is detectable as early as 90 s after stimulation by melittin, by which time EDRF-induced elevation of cGMP in SMCs is maximal (24, (34) (35) (36) . In mixed cultures melittin causes a dose-dependent, endothelium-dependent increase in smooth muscle cGMP which parallels relaxation responses in endothelium-intact rings of rat aorta (35, 36) . Melittin also causes dose-dependent P012 release from endothelial cells in mixed culture. While the doseresponse curve for melittin-induced PGI2 release from mixed cultures is displaced to the right by 10-6 M dexamethasone, EDRF release as measured by cGMP accumulation is unaffected. Quinacrine, another PLA2 inhibitor, has the same effect as dexamethasone. Marked inhibition of melittin-induced AA release by the use of a combination of PLA2 and DAG lipase inhibitors, completely blocks PGI2 production, but does not inhibit EDRF release. The residual melittin-induced AA release that can not be inhibited by PLA2 inhibitors, appears to be due to activation of PLC and the action of DAG lipase.
A dose of ATP, equipotent with melittin in terms of EDRF-induced cGMP accumulation, releases 50% less PGI2. This is consistent with our finding that melittin-induced PLC activation accounts for about 50% of the AA released in response to this agonist, and suggests that ATP-induced PGI2 release may be due to PLA2 activation alone. In keeping with ATP-induced AA release being due solely to PLA2 activation, it is possible to completely inhibit PGI2 release with three PLA2 inhibitors: dexamethasone, hydrocortisone, and quinacrine. Under these conditions, however, EDRF release is significantly augmented by as much as 75%. Furthermore, dexamethasone did not alter endothelium-dependent relaxation in intact rings ofrat aorta, nor did it affect methacholine-induced blood pressure changes in the whole animal. This fall in blood pressure is supposedly endothelium-dependent (37) . Thus, we conclude that the production and release of EDRF, unlike PGI2, is not highly correlated with inhibition of phospholipases.
A clear relationship exists between the release of EDRF and the activation ofguanylate cyclase in SMCs (3, 4, 38) such that, cGMP changes in intact vascular rings and endothelial cell-SMC mixed cultures are acceptable biochemical assays for EDRF (3, 24, 25, 28, 34) . Increased cGMP levels induced by endothelium-dependent vasodilators are associated with relaxation in both a time-and concentration-dependent manner (3, 25, 39) . We used cGMP changes in mixed BAEC-SMC cultures to measure release of EDRF induced by endotheliumdependent vasodilators and confirmed the observation that endothelium has a conditioning effect on the basal level of cGMP in SMCs (24, 28) .
The increases in cAMP following exposure of mixed BAEC-SMC cultures to melittin and ATP may be, in part, due to adenosine and perhaps PGI2 release from the BAECs. Adenosine-and PGI2-induced arterial relaxation is associated with cAMP accumulation in the vessel wall (40, 41) . In addition, PGI2-induced feedback inhibition of prostaglandin production is mediated through elevation of cAMP levels in the endothelium (42) .
Our experiments show that melittin activates PLC as well as PLA2. This was ofconcern to us since PLC activation represents, through the action of DAG lipase on DAG, an alternative source of AA. To address this concern, we successfully inhibited both PLA2 and DAG lipase, and inhibited AA release and PGI2 production by 90%. Despite this, EDRF release was unaffected. Thus, it is possible that melittin-induced EDRF release is mediated through PLC activation and IP3 release, as suggested by the results of Loeb and colleagues (43) .
Our results conflict with the results of previous studies in vessel segments in which certain PLA2 inhibitors were found to inhibit endothelium-dependent relaxation, as well as the associated rise in smooth muscle cGMP concentration (1, 3, 5, 7, 34, [44] [45] [46] (3, 7, 48) . In addition, quinacrine does not inhibit A23187-induced endothelium-dependent relaxation (49) Although glucocorticoids are notorious for their multiplicity of actions, our results with quinacrine which we found to be equally effective at inhibiting PGI2 release and potentiating EDRF release, make it likely that the property they share in common, namely PLA2 inhibition, is somehow involved in potentiating endothelium-dependent relaxation. We have no good explanation for how this may occur, but we believe it is a real phenomenon since we have observed it in the response to two separate endothelium-dependent agonists using three PLA2 inhibitors. In addition, our results confirm an earlier observation suggesting that steroids often potentiate ATP-induced EDRF release in aortic rings (47). This potentiation is probably not due to induction of cytochrome P-450-dependent monooxygenases by steroids, since the cytochrome P-450 isozyme identified in endothelium (cytochrome P-450c) is not steroid-inducible (10, 52, 53) .
Recent reports suggest that EDRF is nitric oxide (14) , while other investigators have suggested that EDRF is a metabolite of AA produced by endothelial cells in smaller amounts than prostaglandins (11-13, 54). It is also possible that more than one substance is responsible for endothelium-dependent relaxation (55, 56 
